MedTrace Logo

Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)

NCT01270711 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22014

Last updated 2014-05-02

Study results available
· View outcomes & findings →

Summary

The overall goal of this study will be to assess and monitor the adherence to and effectiveness of the new prescribing guidelines for cabergoline.

Specific objectives will be to assess: 1. The indication for use of cabergoline (Parkinson, hyperprolactinemia, other) 2. Prior treatment strategies in patients who start cabergoline treatment for Parkinson's Disease 3. The percentage of cabergoline users who are prescribed doses above 3 mg per day 4. Whether cabergoline users are monitored by echocardiography prior and during treatment. 5. The incidence and prevalence of valvular fibrosis

Conditions

Interventions

DRUG

Study Drug

non interventional study - usage as per usual care

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-02-28
Completion
2013-02-28

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01270711 on ClinicalTrials.gov